Demographic, birth, parental characteristics, and the risk of early-onset colorectal cancer: A population-based nested case-control study in California [0.03%]
基于加利福尼亚州的队列病例对照研究的人口统计学、出生及父母特征与早发型结直肠癌风险的关系
Sunny Siddique,Rong Wang,Domenica Berardi et al.
Sunny Siddique et al.
Background: The incidence of early-onset colorectal cancer (EOCRC), defined as colorectal cancer diagnosed before the age of 50 years, has been increasing. The relationship between demographic, birth, and parental charact...
Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib [0.03%]
用于治疗骨转移的雄激素抵抗性前列腺癌患者接受镭-223和奥拉帕利单药或联药治疗后的预后效果及患者报告结果
Rana R McKay,Wanling Xie,Archana Ajmera et al.
Rana R McKay et al.
Background: The combination of olaparib plus radium-223 improved progression-free survival in patients with metastatic castration-resistant prostate cancer with bone metastases (BM) in the multicenter, randomized, phase 2...
Clinical Trial
Cancer. 2026 Jul 1;132(13):e70496. DOI:10.1002/cncr.70496 2026
Magnetic resonance imaging-targeted biopsy with index lesion ipsilateral or bilateral systematic biopsy in prostate cancer: A multicenter, paired, noninferiority, observational trial [0.03%]
基于磁共振影像的前列腺癌目标活检联合同侧或对侧系统穿刺活检的多中心配对非劣效性观察研究：研究论文
Yongbing Cheng,Haifeng Huang,Miao Wang et al.
Yongbing Cheng et al.
Background: Index lesion-focused ipsilateral systematic biopsy (iSB) has been proposed as a core-reduction alternative to MRI-targeted biopsy combined with systematic biopsy (TB + SB) for prostate cancer, but prospective ...
Observational Study
Cancer. 2026 Jul 1;132(13):e70493. DOI:10.1002/cncr.70493 2026
Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study [0.03%]
选择性核转运蛋白抑制剂塞利尼索联合地西他滨或鲁索利替尼治疗骨髓增生异常/骨髓增殖性肿瘤重叠综合征的疗效：一项多中心前瞻性研究
Xijuan Lin,Ziwei Liu,Chen Yang et al.
Xijuan Lin et al.
Background: Therapeutic strategies for myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPNs) remain suboptimal. Selinexor, an oral selective inhibitor of exportin 1, represents a mechanism-based therapeutic app...
Multicenter Study
Cancer. 2026 Jul 1;132(13):e70459. DOI:10.1002/cncr.70459 2026
MASAI trial results support larger scale use of AI-supported mammography [0.03%]
MASAI试验结果支持更大规模地使用人工智能辅助乳腺X线摄影技术
Leah Lawrence
Leah Lawrence
No RFS benefit found from adding vibostolimab to pembrolizumab in patients with high-risk melanoma: Adding the anti-TIGIT antibody vibostolimab to adjuvant pembrolizumab failed to improve recurrence-free survival and increased toxicity [0.03%]
在高危黑色素瘤患者中，帕博利珠单抗联合维泊妥利单抗并未改善无复发生存率并增加毒性：RFS获益的缺乏
Leah Lawrence
Leah Lawrence
Efficacy of a structured rehabilitation program for patients with terminal cancer: A multicenter randomized controlled trial [0.03%]
晚期癌症患者结构化康复方案的疗效研究：多中心随机对照试验
Nanako Nishiyama,Yoshinobu Matsuda,Noriko Fujiwara et al.
Nanako Nishiyama et al.
Background: Maintaining activities of daily living is of great importance for patients who have cancer, and dependency is associated with psychological distress. However, evidence for rehabilitation remains scarce in this...
Randomized Controlled Trial
Cancer. 2026 Jun 15;132(12):e70485. DOI:10.1002/cncr.70485 2026
The Improving Opioid Use for Cancer Pain Framework: Addressing the needs of patients with cancer and pain in a new era of opioid prescribing [0.03%]
癌症疼痛时代改良阿片类药物使用框架：满足癌痛患者在新时代开具阿片类药物的新需求
Sydney M Dy,Ritu Sharma,Julie M Waldfogel et al.
Sydney M Dy et al.
Opioids are essential for cancer pain management, but growing knowledge about their risks and limited effectiveness requires careful consideration in cancer pain guidelines and practice. To better address these issues, an adult cancer pain ...
Comparing the association between out-of-pocket cost burden and cost-related care avoidance among individuals with and without a history of cancer [0.03%]
比较有无癌症病史个体的自付医疗费用负担与因费用问题而避免就医之间的关系
Xi Liang,Djin Tay,Yu Ke et al.
Xi Liang et al.
Introduction: Out-of-pocket (OOP) cost is routinely captured by payers and health systems and may help identify individuals at risk of cost-related care avoidance. This study aimed to evaluate the relationship between OOP...
Comparative Study
Cancer. 2026 Jun 15;132(12):e70495. DOI:10.1002/cncr.70495 2026